Global HPV Testing Market Size to Reach USD 1.54 Billion by 2031 | Growth Insights & Forecasts

Global HPV testing market is undergoing a significant transformation as healthcare systems intensify efforts to eliminate cervical cancer through early and accurate diagnostics. Valued at USD 858 million in 2024, the market is projected to grow from USD 936 million in 2025 to USD 1,545 million by 2031, registering a CAGR of 9.0% during the forecast period. This steady expansion reflects rising screening adoption, technological advancements in molecular diagnostics, and stronger public health commitments worldwide.

Access the complete report https://www.24lifesciences.com/hpv-testing-market-8069

 

Emerging Healthcare Trends Shaping the HPV Testing Market

In 2025 and beyond, several healthcare trends are accelerating the evolution of the HPV testing market. Molecular diagnostics are increasingly prioritized over traditional cytology-based methods due to their higher sensitivity and predictive value. The shift toward HPV primary testing as a first-line screening tool is streamlining workflows and improving detection rates.

Digital health integration, automation in laboratories, and expanding access to diagnostics in low- and middle-income regions are also reshaping market dynamics. Regulatory support for cervical cancer elimination programs and global equity-focused initiatives continue to strengthen long-term demand. According to the World Health Organization (WHO), scaling up HPV testing is central to achieving global cervical cancer elimination targets, reinforcing its public health relevance.

 

Key Market Drivers Supporting Growth

• Rising cervical cancer burden and emphasis on early detection
• Government-backed screening programs and national prevention strategies
• Technological advancements in PCR-based and high-throughput assays
• Growing awareness of HPV-related diseases among patients and clinicians
• Expansion of centralized diagnostic laboratories serving population-wide screening initiatives

Together, these factors are creating a robust and sustainable growth environment for the global HPV testing market.

Review detailed market forecasts https://www.24lifesciences.com/hpv-testing-market-8069

 

Competitive Landscape: Leading Companies

The HPV testing market is characterized by innovation-driven competition, with major diagnostic companies focusing on assay sensitivity, automation, and global accessibility. Key players include:

• Qiagen – Advancing HPV DNA testing platforms with scalable laboratory solutions
• Roche Diagnostics – Strengthening molecular diagnostics portfolios for women’s health
• Hologic, Inc. – Expanding HPV and cervical cancer screening technologies
• Abbott Laboratories – Investing in integrated molecular diagnostics and automation
• BD (Becton, Dickinson and Company) – Enhancing sample collection and diagnostic workflows

These companies are actively investing in R&D, strategic collaborations, and product enhancements to address evolving screening guidelines and regional healthcare needs.

 

Segment Insights & Regional Overview

From a type perspective, co-testing remains the established leader, combining HPV testing with Pap smears to improve diagnostic accuracy. HPV primary testing is rapidly gaining momentum as a standalone screening method, while follow-up HPV testing continues to play a critical role in patient monitoring.

By application, cervical cancer screening dominates the market due to its integration into national prevention programs. Emerging applications in vaginal, anal, and oropharyngeal cancer screening highlight the expanding clinical utility of HPV diagnostics.

Diagnostic laboratories are the leading end users, supported by high-throughput capabilities and centralized testing models. PCR-based assays remain the most widely adopted technology, while next-generation sequencing is emerging in research-driven settings.

Regionally, North America leads the market, driven by advanced healthcare infrastructure, strong reimbursement systems, and early adoption of HPV primary screening. Europe follows with well-established population-based screening programs. The Asia-Pacific region is the fastest-growing market, supported by large-scale government initiatives in China, India, and Australia. South America and the Middle East & Africa present developing opportunities as awareness and healthcare investments increase.

Explore segment-level insights https://www.24lifesciences.com/hpv-testing-market-8069

 

Technological Advancements & Strategic Outlook

Can Innovation-Driven Screening Models Redefine HPV Diagnostics?

The future of the HPV testing market lies in scalable, accurate, and accessible diagnostics. Advances in automation, digital reporting systems, and precision molecular testing are expected to improve screening efficiency while reducing costs. Point-of-care testing solutions and public health-driven deployment models will be critical in expanding access across underserved regions.

 

Key Benefits of the Report

• Comprehensive market size and growth analysis
• Detailed segmentation by type, application, end user, technology, and service provider
• Regional performance insights across five major geographies
• Competitive benchmarking of leading diagnostic companies
• Strategic outlook for investors and healthcare decision-makers

View market analysis https://www.24lifesciences.com/hpv-testing-market-8069

 

Future Perspective

As global healthcare systems prioritize preventive diagnostics and women’s health, the HPV testing market is positioned for sustained expansion. With strong policy backing, technological innovation, and growing awareness, the market offers compelling opportunities for stakeholders seeking alignment with long-term public health and life sciences growth strategies.

 

About 24lifesciences

Founded in 2017, 24LifeScience has emerged as a trusted research and analytics partner for organizations operating within the global life sciences and chemical industries. Our core mission is to provide intelligent, future-ready insights that help clients stay ahead in an increasingly complex and innovation-driven market

International: +1(332) 2424 294 | Asia: +91 9425150513 (Asia)

Website: http://www.24lifesciences.com                                          

Follow us on LinkedIn: http://www.linkedin.com/company/lifesciences24